<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Remdesivir (GS-5734) is a 1â€²-cyano-substituted adenosine nucleotide analog prodrug (RNA-dependent RNA polymerase inhibitor) and shows broad-spectrum antiviral activity against several RNA viruses. According to data collected from in vitro cell lines and mouse model experiments, it could interfere with the nsp12 polymerase even in the setting of intact nsp14 exoribonuclease (ExoN) proofreading activity [
 <xref ref-type="bibr" rid="CR53">53</xref>]. It has been reported to improve the clinical condition of the first US case of COVID-19 [
 <xref ref-type="bibr" rid="CR54">54</xref>]. A phase III clinical trial of remdesivir against SARS-CoV-2 was launched in Wuhan on February 4, 2020. However, it is still an experimental drug not expected to be largely available for treating a very large number of patients in a timely manner. It has to be requested for each individual patient from the manufacturer.
</p>
